IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis

Clinical and Experimental Immunology

Volumn 110, Issue 1, 1997, Pages 114-121

  Till, S ^a   Walker, S ^a   Dickason, R ^b   Huston, D ^b   O'Brien, F ^a   Lamb, J ^c   Kay, A B ^a   Corrigan, C ^a   Durham, S ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Allergy; Cytokines; IL 5; Immunotherapy; T cell

Indexed keywords

ALLERGEN; ALUTARD; GAMMA INTERFERON; INTERLEUKIN 5; PLACEBO; TUBERCULIN;

ADULT; ALLERGIC RHINITIS; ARTICLE; ATOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRASS POLLEN; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRADERMAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POLLEN ALLERGY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0030870124     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1997.494-ce1392.x     Document Type: Article

References (34)

1. Ortolani C, Pastorello E, Moss RB et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984; 73:283-90.
2. Dolz I, Martínez-Cócera C. Bartolomé JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996; 51:489-500.
3. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995; 50:405-13.
4. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hayfever uncontrolled by anti-allergic drugs. Br Med J 1991; 302:265-9.
5. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hayfever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472-82.
6. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Sehi H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991; 21:115-20.
7. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and GM-CSF in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 148:2390-4.
8. Ying S, Durham SR, Barkans J et al. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. Am J Respir Cell Mol Biol 1993; 9:356-60.
9. + T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 92:313-24.
10. Wierenga EA, Snoek M, Jansen HM, Bos JD, van-Lier RA, Kapsenberg ML. Human atopen-specific types 1 and 2 T helper cell clones. J Immunol 1991; 147:2942-9.
11. Imada M, Estelle F, Simons R, Jay FT, Hayglass K. Allergen-stimulated interleukin-4 and interferon-γ production in primary culture: responses of subjects with allergic rhinitis and normal controls. Immunology 1995; 85:373-80.
12. + T cells in primary culture: relationship to expression of allergic disease. J Allergy Clin Immunol 1997; 99:563-9.
13. + T cells from allergic individuals. J Exp Med 1993; 178:2123-30.
14. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.
15. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996; 97:1356-65.
16. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187-94.
17. Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP, Joseph M, Hamid Q, Tonnel AB. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes. Immunology 1996; 87:593-8.
18. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25:828-38.
19. Pienkowski MM, Norman PS, Lichtenstein LM. Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol 1985; 76:729-34.
20. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol 1991; 88:27-32.
21. Iliopoulos O, Proud D, Adkinson NF et al. Effects of immunotherapy on the early, late and rechallenge reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991; 87:855-66.
22. Rothenberg ME, Peterson J, Stevens RL, Silberstein DS, McKenzie DT, Austen KF, Owen WF Jr. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143:2311-6.
23. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167:219-24.
24. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology 1990; 71:258-65.
25. Schweizer RC, Welmers BA, Raaijmakers JA, Zanen P, Lammers JW, Koenderman L. RANTES and interleukin-8-induced responses in normal human eosinophils: effects of priming with interleukin-5. Blood 1994; 83:3697-704.
26. Dickason RR, Huston MM, Huston DP. Enhanced detection of interleukin-5 in biological fluids utilizing murine monoclonal antibodies which delineate distinct neutralizing epitopes. Cytokine 1994; 6:647-56.
27. Parronchi P, Macchia D, Piccinni MP et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile. Proc Natl Acad Sci USA 1991; 88:4538-42.
28. Varney VA, Jacobson MR, Sudderick RM et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis 1992; 146:170-6.
29. +) cells accompany inhibition of allergen induced late skin responses following successful grass pollen immunotherapy.J Allergy Clin Immunol 1997; 99:254-60.
30. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen (s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1T helper or type 2 T helper) profiles of cytokine production. J Clin Invest 1991; 88:346-50.
31. +) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol 1992; 148:2058-61.
32. Maggi E, Parronchi P, Manetti R et al. Reciprocal effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992; 148:2142-7.
33. Manetti R, Parronchi P, Giudizi MG, Piccinni M-P, Maggi E, Trinchieri G, Romagnani S, Natural killer cell stimulatory factor (IL-12) induces T helper type-1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993; 177:1199-204.
34. + T lymphocytes. J Immunol 1995; 155:111-7.